Taguchi Reina, Yamaguchi-Tanaka Mio, Takagi Kiyoshi, Sato Ai, Miki Yasuhiro, Miyashita Minoru, Suzuki Takashi
Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.
Department of Personalized Medicine Center, Tohoku University Hospital, Sendai, Miyagi 980-8575, Japan.
Acta Histochem Cytochem. 2024 Apr 25;57(2):75-83. doi: 10.1267/ahc.24-00006. Epub 2024 Apr 17.
High-mobility group box 1 (HMGB1) functions as damage-associated molecular pattern (DAMPs), released into extracellular space during cellular stress. Extracellular HMGB1 act as signal molecules through Toll-like receptor (TLR) 2 or TLR4, exerting diverse functions in both normal cells and malignant cells including breast cancer. However, their comprehensive examination in breast cancer tissues is lacking. Thus, we immunolocalized them in 112 breast cancer tissues, correlating their immunoreactivity with clinicopathological parameters and clinical outcomes to clarify their significance in breast cancer. We demonstrated that nuclear HMGB1 immunoreactivity was correlated with tumor progression and longer disease-free survival. In contrast, TLR2 immunoreactivity was correlated with increased cell proliferation and shorter disease-free survival, dependent on cytoplasmic HMGB1 immunoreactivity. Additionally, TLR4 immunoreactivity correlated with chemoresistance, regardless of cytoplasmic HMGB1 immunoreactivity. It was therefore considered that TLR2 collaboratively contributed to breast cancer progression with HMGB1-DAMPs to become a worse prognostic factor. Meanwhile, TLR4 served as a worse prognostic factor associated with chemoresistance, irrespective of HMGB1.
高迁移率族蛋白B1(HMGB1)作为一种损伤相关分子模式(DAMPs),在细胞应激时释放到细胞外空间。细胞外HMGB1通过Toll样受体(TLR)2或TLR4作为信号分子,在包括乳腺癌在内的正常细胞和恶性细胞中发挥多种功能。然而,目前缺乏对乳腺癌组织中它们的全面检测。因此,我们对112例乳腺癌组织进行了免疫定位,将它们的免疫反应性与临床病理参数及临床结局相关联,以阐明它们在乳腺癌中的意义。我们发现细胞核HMGB1免疫反应性与肿瘤进展及更长的无病生存期相关。相反,TLR2免疫反应性与细胞增殖增加及更短的无病生存期相关,这依赖于细胞质HMGB1免疫反应性。此外,TLR4免疫反应性与化疗耐药相关,与细胞质HMGB1免疫反应性无关。因此,认为TLR2与HMGB1-DAMPs共同促进乳腺癌进展,成为一个更差的预后因素。同时,TLR4作为一个与化疗耐药相关的更差的预后因素,与HMGB1无关。